@article{9d9c1ddb1c284ac3be15b2cd74cc979c,
title = "Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities",
abstract = "In February 2018, the Melanoma Research Foundation and the Moffitt Cancer Center hosted the Second Summit on Melanoma Central Nervous System (CNS) Metastases in Tampa, Florida. In this white paper, we outline the current status of basic science, translational, and clinical research into melanoma brain metastasis development and therapeutic management. We further outline the important challenges that remain for the field and the critical barriers that need to be overcome for continued progress to be made in this clinically difficult area.",
keywords = "brain metastases, immunotherapy, melanoma, metastasis, targeted therapy",
author = "Zeynep Eroglu and Holmen, {Sheri L.} and Qing Chen and Khushalani, {Nikhil I.} and Ravi Amaravadi and Reena Thomas and Ahmed, {Kamran A.} and Hussein Tawbi and Sunandana Chandra and Joseph Markowitz and Inna Smalley and Liu, {James K.C.} and Chen, {Yian Ann} and Najjar, {Yana G.} and Karreth, {Florian A.} and Daniel Abate-Daga and Glitza, {Isabella C.} and Sosman, {Jeffrey A.} and Sondak, {Vernon K.} and Marcus Bosenberg and Meenhard Herlyn and Atkins, {Michael B.} and Harriet Kluger and Kim Margolin and Forsyth, {Peter A.} and Davies, {Michael A.} and Smalley, {Keiran S.M.}",
note = "Funding Information: on advisory boards for BMS, Incyte, Genentech, and Curis. Nikhil Khushalani serves as an advisor to BMS, AstraZeneca, EMD Serono, Regeneron, Huya Bioscience, Genentech, Array, Immunocore, and Merak and receives research funding from BMS, Merck, Novartis, GSK, Huya Bioscience, Amgen, and Regeneron. Michael Davies is an advisor to BMS, Novartis, Genentech, Array, Vaccinxe, Sanofi‐ Aventis, GSK, and Syndax and serves a consultant to Nanostring. He also receives research funding from AstraZeneca, Genentech, GSK, Myriad, Oncothyreon, and Sanofi‐Aventis. All other authors declare no conflict of interest. Funding Information: We would like to thank the Melanoma Research Foundation for pro- Funding Information: viding financial support for the Melanoma Brain Metastasis summit. Funding Information: Melanoma is the third most common source of brain metastases following lung and breast cancer (Johnson & Young, 1996) and more than 60% of patients with metastatic melanoma either present with or develop brain metastases during the course of their disease (Zakrzewski et al., 2011). Historically, patients with melanoma who developed brain metastases had a very poor prognosis. In December 2015, the Melanoma Research Foundation convened the first summit on melanoma brain metastases (MBM) at the Wistar Institute in Philadelphia, PA, to summarize the current state of MBM research and to provide recommendations on potential focus areas for future basic science, translational, and clinical research (Cohen et al., 2016). The need for clinical trials specifically tailored for patients with MBM and the necessity of further preclinical research in this field were particularly emphasized. Since that first meeting, significant progress has been made, with checkpoint blockade‐based immunotherapy and combination MAP‐kinase targeted therapy improving the outlook for patients with MBM. In February 2018, the second summit on MBM sponsored by the Melanoma Research Foundation was held at the Moffitt Cancer Center, in Tampa, FL. Over 40 participants from around the United States attended, with the goal of providing updates on progress made and outlining the key translational/ clinical gaps that remain. Here, we provide an update on the findings of the second MBM meeting including the current state of therapy for MBM, a summary of ongoing areas of research in basic science and clinical translational studies, key scientific and clinical questions that remain, and recommendations for moving the field forward. A Publisher Copyright: {\textcopyright} 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",
year = "2019",
month = may,
doi = "10.1111/pcmr.12771",
language = "English (US)",
volume = "32",
pages = "458--469",
journal = "Pigment Cell and Melanoma Research",
issn = "1755-1471",
publisher = "Wiley-Blackwell",
number = "3",
}
